<DOC>
	<DOCNO>NCT01388790</DOCNO>
	<brief_summary>This open-label , single-arm , multicenter , Phase 2 trial treat least 40 participant advance gastric adenocarcinoma include adenocarcinoma gastroesophageal junction ( GEJ ) previously receive systemic chemotherapy setting . All eligible participant receive combination cetuximab plus S-1 ( combination tegafur , gimeracil , oteracil ) cisplatin .</brief_summary>
	<brief_title>Cetuximab Combination With S-1 Cisplatin Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Written inform consent agreement medically accept contraception ( participant conception potential ) obtain Japanese participant age great equal 20 year Histologically confirm adenocarcinoma stomach GEJ ( adenocarcinomas esophagogastric junction type I III accord Siewert 's classification ) Stage M0 ( unresectable advance ) Stage M1 ( unresectable metastatic ) disease Archived tumor material sample least subsequent standardize epidermal growth factor receptor ( EGFR ) expression Kirstenrat sarcoma ( KRAS ) mutation assessment At least one radiographically document measurable lesion previously nonirradiated area accord RECIST v 1.0 Eastern Cooperative Oncology Group performance status ( ECOGPS ) 0 1 Estimated life expectancy great 12 week Renal , liver hematopoietic function define protocol . Sodium potassium within normal limit define protocol Other protocol define inclusion criterion could apply Prior therapy : prior treatment antibody molecule target EGFR and/or vascular endothelial growth factor ( VEGF ) receptorrelated signal pathway ; chemotherapy ; radiotherapy , major surgery , investigational drug 30 day start trial treatment Concurrent chronic systemic immune hormone therapy indicate trial protocol contraindication treatment cetuximab cisplatin , treatment prohibit concomitant drug Brain metastasis and/or leptomeningeal disease Clinically relevant coronary artery disease ( New York Heart Association [ NYHA ] functional angina classification III/IV ) , congestive heart failure ( NYHA III/IV ) , clinically relevant cardiomyopathy , history myocardial infarction last 12 month , high risk uncontrolled arrhythmia Chronic diarrhea short bowel syndrome Known Human Immunodeficiency Virus ( HIV ) infection , active chronic carrier hepatitis B virus ( HBV ) ( HBV antigen positive HBV deoxyribonucleic acid ( DNA ) positive ) hepatitis C virus ( HCV ) ( HCV antibody positive ) Pregnancy lactation period Concurrent treatment nonpermitted drug ( chemotherapy , systemic anticancer therapy immunotherapy ) Previous malignancy gastric cancer last 5 year Medical psychological condition would permit participant complete trial sign Informed Consent Form ( ICF ) Legal incapacity limit legal capacity Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Gastric Cancer</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>EMD271786</keyword>
	<keyword>TS-1</keyword>
	<keyword>Cisplatin</keyword>
</DOC>